UCB signs up to $480 million global collaboration with Neuropore on PD

18 January 2015

Neuropore Therapies, a wholly-owned US subsidiary of Austria’s Ever Neuro Pharma, has entered into a worldwide collaboration and agreement with Belgium’s largest drugmaker, UCB (Euronext Brussels: UCB), to develop and commercialize therapeutic products aiming at slowing the progression of Parkinson’s disease (PD) and related disorders.

This includes NPT200-11, Neuropore’s novel small molecule that targets pathogenic alpha-synuclein which is currently in preclinical development and is expected to enter clinical Phase I in 2015. The Parkinson’s disease drug market is currently valued at nearly $3 billion a year and has been forecast to grow to $5 billion by 2022.

$20 million upfront payment

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK